Literature DB >> 15037557

Adverse prognostic significance of new diabetes in treated hypertensive subjects.

Paolo Verdecchia1, Gianpaolo Reboldi, Fabio Angeli, Claudia Borgioni, Roberto Gattobigio, Lucia Filippucci, Silvia Norgiolini, Costanza Bracco, Carlo Porcellati.   

Abstract

Diabetes may develop in nondiabetic hypertensive subjects during treatment, but the long-term cardiovascular implications of this phenomenon are not clear. We determined the prognostic value of new diabetes in hypertensive subjects. In a long-term cohort study, 795 initially untreated hypertensive subjects, 6.5% of whom with type 2 diabetes, underwent diagnostic procedures including 24-hour ambulatory blood pressure (BP) monitoring and electrocardiography (ECG). Procedures were repeated after a median of 3.1 years in the absence of cardiovascular events. Follow-up duration was 1 to 16 years (median 6.0). New diabetes occurred in 5.8% of subjects initially without diabetes. Antihypertensive treatment included a diuretic in 53.5% of these subjects, versus 30.4% of those in whom diabetes did not develop (P=0.002). Plasma glucose at entry (P=0.0001) and diuretic treatment on follow-up (P=0.004) were independent predictors of new diabetes. Subsequent to the follow-up visit, a first cardiovascular event occurred in 63 subjects. Event rate in nondiabetic subjects at both visits, new diabetes, and diabetes at entry were 0.97, 3.90, and 4.70x100 person-years, respectively (P=0.0001). After adjustment for several confounders, including 24-hour ambulatory BP, the relative risk of events was 2.92 (95% CI: 1.33 to 6.41; P=0.007) in the group with new diabetes and 3.57 (95% CI: 1.65 to 7.73; P=0.001) in the group with previous diabetes, when compared with the group persistently free of diabetes. In treated hypertensive subjects, occurrence of new diabetes portends a risk for subsequent cardiovascular disease that is not dissimilar from that of previously known diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037557     DOI: 10.1161/01.HYP.0000125726.92964.ab

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  103 in total

Review 1.  Should two-drug initial therapy for hypertension be recommended for all patients?

Authors:  Jennifer B Cowart; Addison A Taylor
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

2.  Clinical trials report. Adverse prognostic significance of new diabetes in treated hypertensive subjects.

Authors:  Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

3.  Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate.

Authors:  Vassilios G Athyros; Dimitri P Mikhailidis
Journal:  Nat Rev Endocrinol       Date:  2012-02-07       Impact factor: 43.330

Review 4.  Are there benefits of antihypertensive therapy beyond blood pressure lowering?

Authors:  Joseph L Izzo
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

Review 5.  Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice.

Authors:  Samuel Asfaha; Raj Padwal
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

Review 6.  Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.

Authors:  Rhonda M Cooper-DeHoff; Michael A Pacanowski; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

Review 7.  Hypertension and the metabolic syndrome.

Authors:  John A Farmer
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 8.  Antihypertensive treatment and new-onset diabetes mellitus.

Authors:  Tonje Amb Aksnes; Henrik M Reims; Sverre E Kjeldsen; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

Review 9.  Differential effects of antihypertensive drugs on new-onset diabetes?

Authors:  William J Elliott
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

Review 10.  THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.

Authors:  Anna Grodzinsky; Suzanne V Arnold; Dany Jacob; Boris Draznin; Mikhail Kosiborod
Journal:  Endocr Pract       Date:  2016-12-14       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.